UK Spinraza Data Review Shows Benefits Of NICE Flexibility
Biogen has described as “exciting” a first-of-a-kind interim data review that has led to expanded recommendations for the company’s spinal muscular atrophy drug Spinraza.
You may also be interested in...
Evrysdi could follow Spinraza and Zolgensma to become the third treatment for spinal muscular atrophy available on England’s National Health Service if Roche can agree on a lower price for the drug.
More pollical support from the National Health Service and health ministers is needed to ensure the UK’s future as a desirable launch market.
NICE will review new data in deciding whether to OK the use of Spinraza in non-ambulant SMA type III patients.